Latest Market Expansion News

Vitasora Health Limited has secured $4 million in a strongly oversubscribed placement, anchored by a $3 million cornerstone investment from private investor Bob Peters. The capital boost supports rapid growth in monthly billings and funds the company through expected cashflow breakeven in the second half of 2026.

Saferoads Holdings (ASX: SRH) has acquired Chameleon AMLS, adding a new modular trailer product line and appointing its founder Andrew Kaye to the board.

Boresight Ltd (ASX: BST) is seeking to raise $8 million through a public offer to expand its cost-effective military drone manufacturing, targeting growth in the US and European markets.

FOS Capital's Aldridge Traffic Systems subsidiary has landed a $0.5 million contract to supply advanced ITS lighting for the NELP Eastern Freeway Upgrade, marking its largest order since acquisition and boosting the group’s order book to $9 million.

Janus Electric boosts its North American footprint with expanded US orders, significant government subsidies slashing conversion costs, and key infrastructure partnerships advancing.

Control Bionics advances its neural-signal technology across assistive communication, sports, and medical sectors, securing key US reimbursement and distribution agreements while broadening its international footprint.

Harvest Technology Group has appointed Veronica Bainton as CEO, signalling a sharpened focus on defence markets and scaling its Nodestream platform internationally.

4DMedical has landed a three-year commercial contract with SimonMed Imaging, deploying its CT:VQ™ technology across more than 170 US outpatient centres, marking a significant step in its US market expansion.

Elsight has secured a follow-on US$2 million order from a U.S. public safety customer, quadrupling its initial purchase and underscoring growing commercial traction ahead of expected FAA drone rule changes.

Advanced Energy Minerals (ASX:AEM) is ramping up its Cap-Chat high purity alumina production, targeting 3,000 tpa by mid-2026 and planning to double capacity to 6,000 tpa by 2029 amid a forecast supply deficit and surging demand.

Neuren Pharmaceuticals reported a 15% rise in 2025 royalties from DAYBUE®, boosted by strong US sales and a new powder formulation launch. The company is progressing its pivotal Phase 3 trial for NNZ-2591 in Phelan-McDermid syndrome and reassessing capital management amid solid cash reserves.

Australian Vintage Limited has locked in a $128 million refinancing deal extending to 2029 and reported a significant cash flow turnaround in FY26, driven by innovation and strategic acquisitions.